R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Director - Global SOX

Internal Audit & ControlsConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USA

About the Job

Requirements

  • A bachelor's degree or higher in Accounting, Finance, Information Systems, Business Administration, or a related field.
  • At least one relevant certification, such as CPA, CIA, CISA, or equivalent, is expected.
  • At least 12 years of progressive experience in SOX, internal controls, IT audit, public accounting, internal audit, controllership, or related fields.
  • Significant experience leading a SOX 404 program for a publicly traded, multi-entity company with international operations.
  • Deep knowledge of SOX 404, COSO, PCAOB auditing standards, SEC reporting requirements, internal control over financial reporting, management review controls, and financial reporting risk assessment.
  • Strong ITGC and ITAC experience across access, change management, SDLC, computer operations, interfaces, automated controls, key reports, SOC report review, CUECs, and third-party provider controls.
  • Experience supporting global ERP or financial system implementations, upgrades, integrations, or transformations.
  • Strong understanding of close, consolidation, intercompany, foreign currency, SEC reporting, equity, payroll, procurement, accounts payable, treasury, leases, revenue, inventory, and other significant accounting processes.
  • Ability to influence cross-functional and cross-cultural stakeholders, drive accountability, and communicate with senior leaders, auditors, control owners, and technical and non-technical audiences.

Responsibilities

  • Lead the global SOX and ICFR program, including annual planning, scoping, risk assessments, walkthroughs, documentation, testing coordination, deficiency evaluation, remediation tracking, and reporting.
  • Develop a scalable operating model with centralized governance, consistent standards, clear accountability, and right-sized controls that maintain compliance without unnecessary operational burden.
  • Partner with Accounting, SEC Reporting, Technical Accounting, IT, Commercial, Supply Chain, Legal, HR, and regional teams to identify financial reporting risks and ensure controls are well designed, documented, owned, and effective.
  • Maintain SOX documentation, including risk and control matrices, narratives, flowcharts, key reports, management review controls, and regional certifications or attestations.
  • Provide quarterly and annual SOX updates to the Controller, senior management, and the Audit Committee, including status, key risks, deficiencies, and remediation progress.
  • Lead the global ITGC program for enterprise and regional systems supporting financial reporting, including ERP, procurement, payroll, equity, SEC reporting, lease accounting, commercial, inventory, consolidation, and other in-scope applications.
  • Oversee ITGC domains including user access, privileged access, change management, SDLC, computer operations, interfaces, data integrity, cybersecurity dependencies, and third-party providers.
  • Partner with IT, Information Security, system owners, and process owners to assess control implications of new systems, integrations, cross-border data flows, and significant configuration changes.
  • Embed controls by design in system implementations, regional deployments, localizations, and significant process changes, including access provisioning, change management, report validation, and post-implementation readiness.
  • Support controls over commercialization and operational processes, including order-to-cash, gross-to-net, revenue recognition, inventory, third-party logistics, distributors and specialty pharmacies, patient support, government pricing and rebates, and country launches.
  • Serve as the global SOX liaison with internal and external auditors, process owners, IT, Information Security, and other stakeholders to support walkthroughs, testing, evidence submission, and issue resolution.
  • Coordinate the global SOX calendar, PBC requests, control-owner responses, audit deliverables, and consolidated status reporting across regions and time zones.
  • Identify audit bottlenecks, documentation gaps, control design issues, testing matters, and opportunities to simplify or automate controls while maintaining compliance and auditability.
  • Lead evaluation and remediation of control observations and deficiencies, including root cause, severity, impact, remediation plans, and validation of operating effectiveness.
  • Build and develop a high-performing global SOX and ITGC function, including employees, regional resources, consultants, and co-sourced providers.

Desired Qualifications

  • Experience in a global biotech, pharmaceutical, life sciences, or healthcare company preparing for or operating in a commercial-stage environment.
  • Experience with multi-country launch readiness, revenue recognition, gross-to-net, inventory, third-party logistics, government pricing, specialty distributors or pharmacies, or patient support programs.
  • Experience with NetSuite, Coupa, Workday, ADP, equity platforms, Active Disclosure or Workiva, lease and commercial systems, GRC or SOX tools, data warehouses, and reporting platforms.
  • Experience building or scaling an in-house global SOX function, including centralized standards and regional execution.
  • Experience implementing SOX automation, evidence workflows, dashboards, analytics, or AI-enabled monitoring.
  • Public accounting or Big Four or national firm experience.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs